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Abstract
Non-alcoholic fatty liver disease (NAFLD) is strongly associated
with obesity and may progress to non-alcoholic steatohepatitis
(NASH) and liver fibrosis. The deficit of pharmacological therapies
for the latter mainly results from an incomplete understanding of
involved pathological mechanisms. Herein, we identify apoptosis
signal-regulating kinase 1 (ASK1) as a suppressor of NASH and
fibrosis formation. High-fat diet-fed and aged chow-fed liver-
specific ASK1-knockout mice develop a higher degree of hepatic
steatosis, inflammation, and fibrosis compared to controls. In addi-
tion, pharmacological inhibition of ASK1 increased hepatic lipid
accumulation in wild-type mice. In line, liver-specific ASK1 overex-
pression protected mice from the development of high-fat diet-
induced hepatic steatosis and carbon tetrachloride-induced
fibrosis. Mechanistically, ASK1 depletion blunts autophagy, thereby
enhancing lipid droplet accumulation and liver fibrosis. In human
livers of lean and obese subjects, ASK1 expression correlated nega-
tively with liver fat content and NASH scores, but positively with
markers for autophagy. Taken together, ASK1 may be a novel ther-
apeutic target to tackle NAFLD and liver fibrosis.
Keywords autophagy; high-fat diet; NASH
Subject Categories Digestive System; Immunology; Metabolism
DOI 10.15252/emmm.201810124 | Received 25 November 2018 | Revised 30
April 2019 | Accepted 3 May 2019 | Published online 6 June 2019
EMBO Mol Med (2019) e10124
Introduction
Non-alcoholic fatty liver disease (NAFLD) is the most common
chronic liver disease affecting up to 40% of adults and children
(Imajo et al, 2012; Koyama & Brenner, 2017; Friedman et al, 2018).
It has become a major public health problem in developed countries
(Zhang et al, 2016b; Koyama & Brenner, 2017). The spectrum of
NAFLD ranges from simple hepatic lipid accumulation (hepatic
steatosis) to non-alcoholic steatohepatitis (NASH), which can
progress to liver fibrosis, cirrhosis, and hepatocellular carcinoma
(Imajo et al, 2012; Meex et al, 2015; Zhang et al, 2016b). NAFLD is
strongly associated with obesity and obesity-related metabolic disor-
ders such as glucose intolerance, type 2 diabetes (T2D), and dyslipi-
demia (Sun et al, 2012; Zhang et al, 2016b). Increased uptake of
free fatty acids (FFA), elevated de novo lipogenesis, decreased fat
oxidation, reduced hepatic very low-density lipoprotein (VLDL)
secretion, and impaired autophagy may contribute to the develop-
ment of hepatic steatosis (Kohjima et al, 2007; Benhamed et al,
2012; Hur et al, 2016). The latter is induced during nutrient depriva-
tion or stress conditions to maintain cellular homeostasis (Wang,
2015). Besides sequestrating damaged organelles, protein aggre-
gates, and intracellular pathogens (McEwan & Dikic, 2011; Tang
et al, 2012; Wang & Qin, 2013), autophagy degrades lipids, glyco-
gen, and proteins to provide fuel and maintain energy homeostasis
(Czaja, 2011; Gonzalez-Rodriguez et al, 2014; Inokuchi-Shimizu
et al, 2014). Of note, activation of autophagy promotes anti-inflam-
matory pathways (Lodder et al, 2015), and impaired autophagy
induces steatosis and liver fibrosis (Yang et al, 2010; Gonzalez-
Rodriguez et al, 2014; Inokuchi-Shimizu et al, 2014; Stienstra et al,
2014; Lodder et al, 2015).
Fibrosis is the most important predictor of liver-related complica-
tions in NAFLD (Loomba et al, 2017). It is the result of sustained
wound-healing processes in response to chronic hepatocyte injury
leading to inflammatory reaction as well as increased production of
extracellular matrix (ECM) proteins (Berres et al, 2010). Although
initial triggering factors in the development of liver fibrosis remain
largely unknown, the positive effects of autophagy in the preven-
tion of hepatic steatosis and fibrosis (Singh et al, 2009; Yang et al,
2010; Czaja, 2011; Ding et al, 2014; Gonzalez-Rodriguez et al,
2014; Inokuchi-Shimizu et al, 2014; Lodder et al, 2015) have
uncovered therapeutic benefit of pathways regulating autophagy to
tackle NAFLD and liver fibrosis. Since deletion of autophagy genes
may cause neonatal lethality (Takamura et al, 2011), it may be
beneficial to modulate upstream signaling cascades that regulate
autophagy.
Apoptosis signal-regulating kinase 1 (ASK1) is a member of the
mitogen-activated protein kinase kinase kinase (MAP3Ks) family
1 Division of Pediatric Endocrinology and Diabetology, University Children’s Hospital, Zurich, Switzerland
2 Children’s Research Center, University Children’s Hospital, Zurich, Switzerland
3 Zurich Center for Integrative Human Physiology, University of Zurich, Zurich, Switzerland
4 Institute of Food, Nutrition and Health, ETH Zurich, Schwerzenbach, Switzerland
5 Department of Medicine, University of Leipzig, Leipzig, Germany
*Corresponding author. Tel: ++41-44-266 7966; Fax: ++41-44-266 7983; E-mail: daniel.konrad@kispi.uzh.ch
ª 2019 The Authors. Published under the terms of the CC BY 4.0 license EMBO Molecular Medicine 11: e10124 | 2019 1 of 17
and an upstream activator of the c-Jun N-terminal kinase (JNK) and
p38 MAPK signaling cascades (Ichijo et al, 1997; Ichijo, 1999;
Hsieh & Papaconstantinou, 2006; Imoto et al, 2006). ASK1 is acti-
vated by various stressors such as reactive oxygen species (ROS),
tumor necrosis factor alpha (TNF-a), endoplasmic reticulum (ER)
stress, and lipopolysaccharides (LPS; Imoto et al, 2006; Rudich
et al, 2007; Saito et al, 2007; Tobiume et al, 2002), placing ASK1
as a signaling node in which different stressors converge. These
stress signals phosphorylate ASK1 to subsequently induce activa-
tion of JNK and p38 MAPK (Pan et al, 2010; Nakagawa et al,
2011). In turn, activated JNK and p38 MAPK regulate autophagy,
thereby modulating apoptosis, proliferation, and inflammation to
maintain cellular integrity (Ichijo et al, 1997; Tobiume et al,
2001; McEwan & Dikic, 2011; Nakagawa et al, 2011; Sui et al,
2014). In support of an important role of ASK1 in the regulation
of autophagy, whole body ASK1-knockout mice are highly suscep-
tible to lethal bacterial infection due to blockage of autophagy in
the liver (Gade et al, 2014). Herein, we hypothesized that liver-
specific ASK1 plays a crucial role in the regulation of hepatocyte
autophagy and, consequently, in the development of NAFLD and
fibrosis.
Results
Decreased liver ASK1 expression in human subjects with hepatic
steatosis and NASH
To assess whether ASK1 may contribute to the development of
hepatic steatosis and NASH in humans, we analyzed ASK1 mRNA
expression in the liver of lean and obese subjects with or without
type 2 diabetes. Basic clinical characteristics of these subjects are
provided in Appendix Table S1. We found significant negative corre-
lations between liver ASK1 expression and BMI, plasma alanine
aminotransferase (ALAT), and liver fat content (Fig 1A–C). ASK1
expression was significantly reduced in patients with elevated NASH
scores (Fig 1D). Moreover, ASK1 expression correlated positively
with the autophagy marker autophagy-related gene 5 (ATG5), 7
(ATG7), and 12 (ATG12) expression (Fig 1E–G). These data suggest
a protective role for liver-expressed ASK1 in the development of
hepatic steatosis as well as NASH in humans, potentially via regulat-
ing autophagy.
Depletion of hepatic ASK1 increases lipid storage
To elucidate a potential role of ASK1 in hepatic lipid accumulation,
experiments in cultured hepatocytes were performed. As shown in
Appendix Fig S1A, ASK1 protein is expressed in HepG2 cells and
treatment with palmitate and/or rapamycin increased its phosphory-
lation. The latter is a well-known activator of ASK1 and autophagy
(Huang et al, 2004; Gonzalez-Rodriguez et al, 2014). As expected,
rapamycin significantly decreased palmitate-induced lipid droplet
accumulation in hepatocytes (Osawa et al, 2011; Fig 2A). To assess
the involvement of ASK1 in rapamycin-induced lipid clearance,
ASK1 was depleted in HepG2 cells using siRNA targeting ASK1
(siASK1; Fig 2B and Appendix Fig S1B). As expected, ASK1 silenc-
ing decreased phosphorylation of its downstream target JNK in
hepatocytes treated with BSA or palmitate (Appendix Fig S1C).
Compared to cells transfected with non-targeting control siRNA
(siCtrl), ASK1 depletion significantly increased lipid droplet accumu-
lation in hepatocytes treated with or without palmitate (Fig 2C;
Appendix Fig S1D). Importantly, the effect of rapamycin on the
clearance of palmitate-induced lipid accumulation was decreased in
ASK1-depleted hepatocytes (Fig 2C; Appendix Fig S1D), suggesting
that ASK1 is involved in the clearance of lipid accumulation in
hepatocytes.
Next, we aimed to determine whether ASK1 affects autophagy in
cultured hepatocytes. To this end, we assessed levels of LC3-II and
p62, two proteins known to be accumulated by blocked autophagy
(Bjorkoy et al, 2005; Klionsky et al, 2012; Gonzalez-Rodriguez et al,
2014). Indeed, accumulation of LC3-II and p62 protein levels was
increased in ASK1-depleted hepatocytes, indicating blunted autop-
hagy (Fig 2D and Appendix Fig S1E). Consistently, LC3-II punctu-
ates were clearly increased in ASK1-depleted hepatocytes compared
to siCtrl cells (Fig 2E). Double immunofluorescence staining
revealed increased colocalization of lipid droplets with LC3-II punc-
tuates in ASK1-depleted cells (Fig 2E and Appendix Fig S1F). Of
note, the observed heterogeneous individual cell response was con-
firmed in independent experiments.
To investigate a causative role of autophagy, experiments with
the autophagy inhibitor bafilomycin were performed. In agreement
with previous experiments, ASK1 knockdown significantly
increased LC3 colocalization with lipid droplets in BSA-treated cells
(Fig 2F), indicating blunted lipophagy (Singh et al, 2009). As
expected from previous observation (Pi et al, 2015), blockage of
autophagy significantly increased LC3 accumulation in siCtrl hepa-
tocytes. However, such effect was clearly blunted in ASK1-depleted
cells (siCtrl 227  41% vs. siASK1 49  9%, P < 0.01), indicating
that impaired autophagy contributes to increased LC3 accumulation
in siASK1-treated hepatocytes. Next, lipid accumulation was
assessed after bafilomycin treatment. Similar to data presented in
Fig 2C, ASK1 depletion significantly increased lipid droplet accumu-
lation in hepatocytes treated with or without palmitate (Fig 2G).
Importantly, treatment with bafilomycin significantly enhanced lipid
droplet accumulation in siCtrl cells, whereas such effect was blunted
in siASK1-treated cells. Taken together, our data indicate that deple-
tion of ASK1 in hepatocytes induces lipid accumulation, potentially
via blunting autophagy.
Hepatocyte-specific ASK1-knockout mice develop NASH
and fibrosis
To investigate the role of hepatic ASK1 in liver lipid metabolism
in vivo, liver-specific ASK1-knockout mice (ASK1Dhep) were gener-
ated using the Cre-lox system (Postic et al, 1999). As controls, litter-
mate mice that do not express albumin promoter-driven Cre
recombinase (Cre) were used (ASK1F/F). Western blot analysis con-
firmed the deletion of ASK1 protein in the liver of ASK1Dhep mice,
whereas its expression was comparable between ASK1Dhep and
ASK1F/F mice in all other tissues examined (Appendix Fig S2A). To
determine the metabolic relevance of hepatocyte-specific ASK1 abla-
tion on NAFLD and liver fibrosis formation, mice were fed either a
standard chow or a high-fat diet (HFD) for 20 weeks. While HFD-
fed mice revealed higher body weight compared to chow-fed mice,
ASK1Dhep and ASK1F/F mice showed similar body weight gain,
regardless of diet (Appendix Fig 2B). Fat pad mass was similar
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Figure 1. Decreased liver ASK1 expression in human subjects with hepatic steatosis and NASH.§
A–C Scatter plot and correlation coefficient (r) of ASK1 mRNA expression and BMI (A), plasma alanine aminotransferase (ALAT) (B), and liver fat content (C).
D ASK1 mRNA expression in patients with different NASH scores.
E–G Scatter plot and correlation coefficient (r) of ASK1 mRNA expression and ATG5 (E), ATG7 (F), and ATG12 (G) mRNA expression.
Data information: Data were collected in lean subjects (n = 14), obese subjects (n = 23), and obese subjects with type 2 diabetes (n = 19). Values are expressed as
mean  SEM (D). ***P < 0.001, ****P < 0.0001. Statistical tests used are as follows: Spearman correlation for (A, B, C, E, F and G); and ANOVA for (D).
Source data are available online for this figure.
§Correction added on 9 October 2019, after first online publication: source data for Figure 1 have been added.
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between both genotypes under either diet (Appendix Fig S2C),
whereas ASK1Dhep mice showed slightly increased liver weight
under both chow and HFD compared with ASK1F/F mice
(Appendix Fig S2D). Importantly, aggravated hepatic lipid droplet
accumulation and significantly higher liver triglyceride (TG) content
were observed in HFD-fed ASK1Dhep (Fig 3A and B) demonstrating
that ASK1 ablation accelerated HFD-induced hepatic steatosis.
In agreement with elevated hepatic steatosis, mRNA expression
of hepatic perilipin (Plin), a gene promoting lipid droplet formation
and known to be elevated in fatty livers (Trevino et al, 2015), was
significantly increased in HFD-fed ASK1Dhep compared with ASK1F/F
mice (Fig 3C). In contrast, similar expression of genes involved in
lipolysis (Lipe/Hsl), de novo lipogenesis (Acc1, Fas, and Srebp1),
and b-oxidation (Cpt1a, Acox, and Ppara) was observed in livers of
both genotypes (Appendix Fig S2E). In HFD-fed ASK1Dhep mice,
expression of hepatic very low-density lipoprotein receptor (Vldlr)
was significantly upregulated (Fig 3C), suggesting that ASK1 inhibi-
tion may enhance VLDL uptake or block its secretion, thereby
increasing liver triglyceride accumulation.
Hepatic lipid storage is tightly associated with impaired glucose
metabolism and chronic hepatic inflammation (Dowman et al, 2010;
Yang et al, 2010). Indeed, HFD-fed ASK1Dhep mice showed slightly
impaired glucose tolerance (Appendix Fig S2F) as well as increased
plasma insulin levels (Appendix Table S2) when compared to ASK1F/F
mice indicating that ASK1 deficiency may enhance HFD-induced
glucose intolerance. Although 50% higher in knockout animals, circu-
lating insulin levels did not significantly differ between the two geno-
types. No difference in glucose tolerance between the two genotypes
was observed in age-matched chow-fed mice (Appendix Fig S2F). In
addition, expression of pro-inflammatory cytokines and macrophage
markers Il-6, F4/80, and Mcp-1(Ccl2) was elevated in livers of
ASK1Dhep mice (Fig 3D). In line with increased hepatic inflammation,
plasma levels of alanine transaminase (ALT) and aspartate amino-
transferase (AST) were markedly elevated in ASK1Dhep mice
(Appendix Table S2). Hence, ASK1 depletion stimulates hepatic
inflammation/injury and consequently the progression of hepatic
steatosis to NASH. Circulating cytokine levels were similar between
both genotypes (Appendix Table S2), indicating that hepatic ASK1
ablation is mainly influencing local liver inflammation. In addition,
plasma glycerol, FFA, TG, and cholesterol levels were comparable
(Appendix Table S2). Collectively, these data indicate that hepatic
depletion of ASK1 accelerates HFD-induced development of hepatic
steatosis and NASH.
We next wanted to investigate whether ASK1 is involved in the
progression of NASH to liver fibrosis (Dowman et al, 2010). After
20 weeks of HFD, mRNA expression of Col1a1 and Tgfb1 was signif-
icantly higher in livers of HFD-fed ASK1Dhep mice (Fig 3E), indicat-
ing elevated collagen/fibrogenic cytokine expression in knockout
mice. In agreement, collagen deposition as assessed by Sirius Red
staining was markedly increased in liver-specific ASK1-knockout
mice (Fig 3F and G) revealing the development of liver fibrosis. In
addition, immunohistochemical analysis revealed upregulated
alpha-smooth muscle actin (a-SMA) protein levels in the liver of
HFD-fed ASK1Dhep mice (Fig 3H). This suggests that activation of
fibrogenic hepatic satellite cells contributed to increased collagen
production (Lim et al, 2011). In agreement, protein levels of colla-
gen 1A1 were significantly increased in HFD-fed-knockout mice
(Fig 3I). To investigate whether liver-expressed ASK1 impacts on
age-related development of fatty liver and fibrosis, we analyzed
livers of 15-month-old chow-fed control and knockout mice. Indeed,
aged ASK1Dhep mice revealed elevated hepatic TG levels as well as
higher collagen deposition as assessed by Sirius Red staining (Fig 3J
and K). In addition, ASK1Dhep mice showed impaired glucose
tolerance compared to ASK1F/F mice at the age of 15 months
(Appendix Fig S3A), indicating that ASK1 deficiency aggravates
age-induced glucose intolerance. Hence, liver ASK1 protects from
HFD- and age-induced development of NASH and fibrosis.
Autophagy is impaired in hepatocyte-specific
ASK1-knockout mice
In support of an important role of ASK1 in JNK activation, phospho-
rylation of the latter was significantly reduced in livers of hepato-
cyte-specific ASK1-depleted mice fed a HFD for 20 weeks (Fig 4A)
as was phosphorylation of p38 MAPK (Fig 4A). Activated JNK may
activate autophagy via inducing activation of Beclin 1 (BCN1;
McEwan & Dikic, 2011; Gade et al, 2014). In line with reduced p-
JNK protein levels, phosphorylation of BCN1 was downregulated in
ASK1Dhep compared to ASK1F/F mice (Fig 4A). Moreover, accumula-
tion of LC3-II and aggregation of autophagy substrate p62 protein
levels were markedly elevated in ASK1Dhep mice (Fig 4A) indicating
impaired hepatic autophagy. In agreement, protein levels of the
◀ Figure 2. Depletion of hepatic ASK1 increases lipid storage.A Hepatocytes were treated with BSA, Palm, or Palm + Rap for 24 h. Cells were stained for lipid droplet accumulation (BODIPY 493/503, green) and nuclei (Hoechst,
blue). Lipid accumulation was quantified using automated image-based analysis (n = 4 biological replicates). Scale bar represents 100 lm.
B Shown is one representative Western blot from two independent experiments of hepatocytes transfected with siRNA targeting ASK1 (siASK1) or non-targeting siRNA
control (siCtrl).
C Lipid accumulation was quantified using automated image-based analysis in ASK1-knockdown (siASK1; gray bars) or control (siCtrl; black bars) cells treated with BSA,
Palm, and Palm + Rap and stained as mentioned above (n = 4 biological replicates).
D Shown is one representative Western blot from two independent experiments (left) and quantification of LC3-II/I and p62 protein levels Palm (right).
E Colocalization of in siCtrl (n = 4 biological replicates) or siASK1 (n = 4 biological replicates) cells treated with LC3-II punctate (red) with lipid (BODIPY 493/503, green)
and nuclei (Hoechst, blue) in siCtrl or siASK1 cells treated with BSA, Palm, or Palm + Rap. Scale bar represents 100 lm.
F Colocalization of LC3-II punctate with lipid droplets (BODIPY 493/503, green) was quantified in hepatocytes transfected with siRNA targeting ASK1 (siASK1; gray bars)
or non-targeting siRNA control (siCtrl; black bars) and treated with BSA or BSA + Baf for 24 h (n = 4 biological replicates).
G Lipid accumulation was quantified using automated image-based analysis in ASK1-knockdown (siASK1; gray bars) or control (siCtrl; black bars) cells treated with BSA,
Palm, or Palm + Baf and stained as mentioned above (n = 4 biological replicates).
Data information: Values are expressed as mean  SEM. *P < 0.05; **P < 0.01; ***P < 0.001. Statistical tests used are as follows: ANOVA for (A, C, F, and G); and t-test
for (D).
Source data are available online for this figure.
ª 2019 The Authors EMBO Molecular Medicine 11: e10124 | 2019 5 of 17
Tenagne D Challa et al EMBO Molecular Medicine
Il-6 F4/80 Mcp1
0
1
2
3
Re
la
tiv
e
m
RN
A
ex
pr
es
si
on
(fo
ld
)
* *
#
ASK1F/F ASK1Δhep
0
5
10
15
Si
riu
s
Re
d
po
si
tiv
e
ar
ea
(%
)
***
Col1a1 Tgfß1
0
1
2
3
Re
la
tiv
e
m
RN
A
ex
pr
es
si
on
(fo
ld
)
* *
ASK1F/F
Chow
ASK1Δhep
Chow
ASK1F/F
HFD
ASK1Δhep
HFD
0
50
100
150
Li
ve
rT
G
(μ
m
ol
/g
liv
er
) *
***
***
Plin Vldlr
0
1
1
2
2
Re
la
tiv
e
m
RN
A
ex
pr
es
si
on
(fo
ld
)
* *
B
ASK1F/F ASK1ΔhepE
A
C D
F
HG
ASK1ΔhepASK1F/F
ASK1F/F ASK1Δhep
0
1
2
3
4
Co
l1
A1
/H
SP
90 *
I
100HSP90
COL1A1 70
ASK1F/F ASK1Δhep
α-SMA/DAPI
ASK1F/F ASK1Δhep
ASK1F/F ASK1Δhep
0
2
4
6
Si
riu
s
Re
d
po
si
tiv
e
ar
ea
(%
)
***
ASK1F/F ASK1Δhep
0
20
40
60
80
Li
ve
rT
G
(μ
m
ol
/g
liv
er
) #
J K
Figure 3.
6 of 17 EMBO Molecular Medicine 11: e10124 | 2019 ª 2019 The Authors
EMBO Molecular Medicine Tenagne D Challa et al
autophagy marker ATG12 were significantly reduced further indicat-
ing blunted autophagy in knockout mice (Fig 4A). The latter was
further verified by LC3-II immunostaining. Consistent with
increased LC3-II protein levels, LC3-II punctuates were higher in
liver sections of ASK1Dhep compared with ASK1F/F mice (Fig 4B),
suggesting that HFD feeding impairs autophagy in liver-specific
ASK1-deficient mice. Similarly, accumulation of LC3-II and p62
protein levels was significantly elevated in 15-month-old ASK1Dhep
mice (Appendix Fig S3B–D). Collectively, these data indicate that
hepatic ASK1 depletion accelerates HFD-induced blockage of autop-
hagy, potentially contributing to impaired clearance of liver lipids.
Depletion of ASK1 impairs autophagy in primary hepatocytes
To determine whether reduced autophagy in ASK1-depleted hepato-
cytes contributes to elevated lipid accumulation, experiments in
primary hepatocytes treated with the autophagy inhibitor bafilo-
mycin were performed. In line with experiments in HepG2 cells,
rapamycin significantly decreased palmitate-induced lipid droplet
accumulation in hepatocytes isolated from ASK1F/F but not from
ASK1Dhep mice (Fig 5A). Bafilomycin blunted the effect of rapa-
mycin on the clearance of palmitate-induced lipid droplet accumula-
tion only in hepatocytes isolated from control mice (Fig 5A),
indicating that blunted autophagy in ASK1-depleted hepatocytes
contributes to elevated lipid accumulation. Of note, LC3-II punctu-
ates were increased in ASK1-depleted hepatocytes treated with BSA
compared to control cells (Fig 5B), further suggesting that lack of
ASK1 inhibits autophagy. In line with experiments performed in
HepG2 cells (Fig 2E), treatment with rapamycin reduced palmitate-
induced lipid droplet colocalization with LC3-II punctuates in hepa-
tocytes isolated from control mice, whereas it had no effect in
ASK1-depleted cells. As expected, the autophagy inhibitor bafilo-
mycin increased LC3-II punctuates in control cells (Fig 5B).
Pharmacological inhibition of ASK1 aggravates HFD-induced
hepatic lipid accumulation
Given the suggested role of hepatic ASK1 ablation in the pathogene-
sis of NAFLD, we evaluated the therapeutic effects of pharmacologi-
cal ASK1 inhibition. C57BL/6J mice fed a HFD for 11 weeks were
treated with or without an ASK1 inhibitor for the last 5 weeks of
HFD feeding. Mice treated with the ASK1 inhibitor showed similar
body weight gain compared to control mice (data not shown). As
expected, treatment with the ASK1 inhibitor significantly decreased
hepatic ASK1 phosphorylation compared to control mice (Fig 6A).
In line with results obtained from ASK1Dhep mice, treatment with
the ASK1 inhibitor markedly aggravated HFD-induced hepatic lipid
droplet accumulation and liver TG content (Fig 6B and C). In paral-
lel, higher fasting blood glucose and increased plasma FFA and TG
levels were detected in mice treated with the ASK1 inhibitor
(Appendix Table S3). Pharmacological inhibition of ASK1 markedly
downregulated activation of the JNK-autophagy axis, as evidenced
by reduced phosphorylation of JNK and BCN1, accompanied by
increased LC3-II and p62 protein levels compared to control mice
(Fig 6A). Taken together, pharmacological inhibition of ASK1
impairs hepatic autophagy and increases HFD-induced liver lipid
accumulation.
Liver-specific ASK1 overexpression ameliorates HFD-induced
steatosis and protects from CCl4-induced fibrosis
To investigate a regulatory role of liver ASK1 in the development of
steatosis and fibrosis, mice with liver-specific overexpression of
ASK1 were generated (ASK1+hep). After Cre-lox-mediated excision
of the stop cassette, such mice express ASK1 under the ROSA26
promoter (Casola, 2010). Accordingly, albumin promoter-driven
Cre expression promotes overexpression of ASK1 specifically in the
liver (Appendix Fig S4A). ASK1+hep and control littermate mice
(ASK1F/F) were fed a HFD for 20 weeks. Glucose tolerance was
significantly improved in HFD-fed liver-specific ASK1 overexpress-
ing compared to control mice (AUC ASK1F/F 2,267  195 mmol/
l*min vs. ASK1+hep 1,615  116 mmol/l*min; P < 0.05). Lower
hepatic lipid droplet accumulation and significantly reduced liver
TG content were observed in HFD-fed ASK1+hep compared with
control mice (Fig 7A and B), suggesting that ASK1 overexpression
blunts HFD-induced hepatic steatosis. In parallel, autophagy was
elevated in HFD-fed ASK1+hep mice (Fig 7C and Appendix Fig S4B).
Next, we wanted to elaborate whether ASK1 overexpression
protects from carbon tetrachloride (CCl4)-induced fibrosis (Meder-
acke et al, 2013). Indeed, collagen deposition as assessed by Sirius
◀ Figure 3. Hepatocyte-specific ASK1-knockout mice develop NASH and fibrosis.A Representative images of liver sections stained with H&E from mice fed a HFD for 20 weeks. Scale bar represents 100 lm.
B Liver triglyceride (TG) content of mice fed a chow (ASK1F/F n = 6 mice; ASK1Dhep n = 6 mice) or HFD (ASK1F/F n = 14 mice; ASK1Dhep n = 15 mice).
C Relative mRNA expression of perilipin (Plin) and very low-density lipoprotein receptor (Vldlr) in liver of mice fed a HFD for 20 weeks [ASK1F/F n = 6 mice; ASK1Dhep
n = 7 mice (Vldlr) or n = 8 mice (Plin)].
D Relative mRNA expression of genes involved in inflammation in liver of mice fed a HFD for 20 weeks (ASK1F/F n = 6 mice; ASK1Dhep n = 7 mice (F4/80, Mcp1) or
ASK1Dhep n = 8 mice (Il-6)).
E Relative mRNA expression of collagen, type I, alpha 1 (Col1a1) (ASK1F/F n = 11 mice; ASK1Dhep n = 15 mice), and transforming growth factor beta 1 (Tgfb1) (ASK1F/F
n = 6 mice; ASK1Dhep n = 8 mice) in liver of HFD-fed mice.
F, G (F) Representative images of liver sections stained with Sirius Red (scale bar represents 100 lm) and (G) quantification of Sirius Red-positive area in liver of mice
fed a HFD (ASK1F/F n = 8 mice; ASK1Dhep n = 8 mice).
H Representative images of liver sections stained with a-SMA from mice fed a HFD for 20 weeks. Scale bar represents 100 lm.
I Shown is one representative Western blot from two independent experiments (left) and quantification of hepatic COL1A1 protein levels in mice fed a HFD for
20 weeks (ASK1F/F n = 8 mice; ASK1Dhep n = 8 mice) (right).
J, K Liver triglyceride (TG) content (ASK1F/F n = 7 mice; ASK1Dhep n = 7 mice) and quantification of Sirius Red-positive area in livers (ASK1F/F n = 7 mice; ASK1Dhep n = 7
mice) of 15-month-old chow-fed mice.
Data information: Values are expressed as mean  SEM. #P = 0.08; *P < 0.05; ***P < 0.001. Statistical tests used as follows: ANOVA for (B); and t-test for (C, D, E, G, I, J, and K).
Source data are available online for this figure.
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Figure 4. Autophagy is impaired in hepatocyte-specific ASK1-knockout mice.
A Shown is one representative Western blots from two independent experiments (left) and quantification of respective protein levels in mice fed a HFD for 20 weeks
(ASK1F/F n = 8 mice; ASK1Dhep n = 8 mice) (right). Values are expressed as mean  SEM. **P < 0.01; ***P < 0.001. Statistical test used is as follows: t-test.
B Representative immunofluorescence images of liver sections stained for LC3-II punctate (red) and nuclei (DAPI, blue) in mice. Scale bar represents 100 lm.
Source data are available online for this figure.
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Red staining was significantly lower in livers of CCl4-injected
ASK1+hep mice (Fig 7D). In parallel, mRNA expression of pro-
inflammatory cytokines as well as macrophage and fibrosis markers
including Col1a1 and Tgfb1 was reduced (Fig 7E and F). Taken
together, liver-specific overexpression of ASK1 protects from the
development of HFD-induced steatosis and CCl4-induced fibrosis.
Discussion
The present study uncovers a protective role of liver-expressed
ASK1 in the development of NAFLD and liver fibrosis. Such notion
is supported by the fact that genetic depletion and pharmacological
inhibition of ASK1 in vivo and in vitro increased hepatic lipid droplet
accumulation and/or liver fibrosis, potentially via blocking autop-
hagy function. In line, liver-specific ASK1 overexpression protected
mice from HFD-induced steatosis and CCl4-induced fibrosis. In
human livers of lean and obese subjects, ASK1 expression was nega-
tively associated with liver fat content and NASH scores, but corre-
lated positively with the autophagy markers ATG5, ATG7, and
ATG12.
Autophagy plays an important role in hepatic lipid homeostasis.
In fact, lipid droplets are substrates of autophagy, since they are
sequestered in autophagosomes for degradation within lysosomes
(Singh et al, 2009). In HFD-fed ASK1Dhep mice, we found decreased
autophagy as determined by reduced protein levels of ATG12 as
well as increased accumulation of LC3-II and p62. Of note, activa-
tion of autophagy decreases accumulation of LC3-II and p62,
whereas blockage of autophagy increases LC3-II and p62 protein
levels (Bjorkoy et al, 2005; Klionsky et al, 2012; Gonzalez-Rodri-
guez et al, 2014). Reduced autophagy in ASK1Dhep mice was
paralleled by elevated liver lipid accumulation indicating that
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Figure 5. Depletion of ASK1 impairs autophagy in primary hepatocytes.
A Primary hepatocytes isolated from chow-fed ASK1F/F (grey bars) and ASK1Dhep (green bars) mice were treated with BSA, Palm, Palm + Rap, or Palm + Rap + Baf for
24 h. Cells were stained for lipid droplet accumulation (BODIPY 493/503, green) and nuclei (Hoechst, blue). Lipid accumulation was quantified using automated image-
based analysis (n = 4 biological replicates). Values are expressed as mean  SEM. *P < 0.05; **P < 0.01; ***P < 0.001. Statistical test used is as follows: ANOVA.
B Colocalization of LC3-II punctate (red) with lipid (BODIPY 493/503, green) and nuclei (Hoechst, blue) in primary hepatocytes treated with BSA, Palm, Palm + Rap, or
Palm + Rap + Baf. Scale bar represents 100 lm.
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Figure 6. Pharmacological inhibition of ASK1 induces hepatic lipid accumulation.
A Western blots (left) and quantification of respective protein levels in liver of HFD-fed mice treated with or without ASK1 inhibitor (n = 4 mice per treatment)
(right).
B, C (B) Representative images of liver sections stained with H&E (scale bar represents 100 lm) and (C) liver triglyceride (TG) content of HFD-fed mice treated with or
without ASK1 inhibitor (n = 8 mice per treatment).
Data information: Values are expressed as mean  SEM. *P < 0.05; **P < 0.01. Statistical test used is as follows: t-test for (A, C).
Source data are available online for this figure.
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Figure 7. Liver-specific ASK1 overexpression ameliorates HFD-induced steatosis and protects from CCl4-induced fibrosis.
A Representative images of liver sections stained with H&E from mice fed a HFD for 20 weeks. Scale bar represents 100 lm.
B Liver triglyceride (TG) content (ASK1F/F n = 11 mice; ASK1+hep n = 10 mice) in livers of mice fed a HFD for 20 weeks.
C Western blots (left) and quantification of protein levels of respective targets in liver of HFD-fed mice (n = 8 mice per genotype for p-JNK and ATG12, n = 4 mice per
genotype for pBCN1) (right).
D Quantification of Sirius Red-positive area (ASK1F/F n = 11 mice; ASK1+hep n = 9 mice) in livers of CCl4-injected mice.
E, F Relative mRNA expression (ASK1F/F n = 13 mice; ASK1+hep n = 14 mice) of respective genes involved in inflammation and fibrosis in liver of CCl4-injected mice.
Data information: Values are expressed as mean  SEM. #P < 0.1; *P < 0.05; **P < 0.01; ***P < 0.001. Statistical test used is as follows: t-test for (B–F).
Source data are available online for this figure.
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blunted autophagy may be critically involved in the observed
phenotype. In support for an important role of autophagy in
ASK1’s effect on hepatic lipid accumulation, blockage of autop-
hagy affected lipid accumulation in control cells but not in hepa-
tocytes with siRNA or Cre-lox-mediated ASK1 depletion.
Moreover, colocalization of lipid droplets with LC3 punctuates
was increased in ASK1-depleted cells, indicating blunted lipo-
phagy. As previously reported (Wang et al, 2017a), lipid droplets
and LC3 puncta in hepatocytes were present in parallel rather
than overlapping. In line with findings in mice with genetic ASK1
depletion, pharmacological inhibition of ASK1 accelerated HFD-
induced lipid droplet storage and liver TG content in C57BL/6J
mice. In the latter mice, elevated steatosis was accompanied by
enhanced accumulation of LC3-II and p62 protein levels suggest-
ing impaired hepatic autophagy. Similarly, ASK1 knockdown in
hepatocytes in vitro resulted in higher lipid accumulation and
increased accumulation of LC3-II and p62 protein levels.
The ASK1 downstream target JNK was shown to regulate autop-
hagy via activation of BCN1 (McEwan & Dikic, 2011). In HFD-fed
mice, we found reduced p-JNK and p-BCN1 levels after genetic as
well as pharmacological inhibition of ASK1, indicating that ASK1
regulates hepatic lipid accumulation via the JNK-autophagy axis. In
support of latter axis, JNK inhibition blunted autophagy in hepato-
cytes (Zhang et al, 2016a; Wang et al, 2018). In agreement with our
findings, hepatic JNK1-knockout mice develop hepatic steatosis
(Sabio et al, 2009). In such mice, impaired VLDL assembly contrib-
uted to elevated lipid accumulation. Moreover, a previous study has
reported increased hepatic lipid accumulation induced by VLDLR
overexpression, while VLDLR-deficient mice were protected from
hepatic steatosis induced by HFD feeding (Jo et al, 2013). Further-
more, activation of autophagy degrades VLDL assembly to decrease
hepatic lipid storage (Conlon et al, 2016; Zamani et al, 2016).
Hence, increased expression of Vldlr in HFD-fed ASK1Dhep mice may
contribute to elevated hepatic steatosis in ASK1-knockout mice via
reduced activation of the JNK-autophagy axis.
Besides affecting lipid accumulation (Singh et al, 2009; Gonza-
lez-Rodriguez et al, 2014), defective autophagy may also be
involved in the development of NASH and liver fibrosis
(Inokuchi-Shimizu et al, 2014; Lodder et al, 2015). In fact, mice
lacking ATG5 in macrophages develop elevated liver injury and
fibrosis induced by carbon tetrachloride treatment due to
increased Il-1b expression (Lodder et al, 2015). Such data
suggest that autophagy suppresses liver fibrosis by regulating
inflammatory pathways. Moreover, liver-specific ATG7 and
ATG5-deficient mice developed multiple liver tumors due to p62
accumulation (Takamura et al, 2011). In line with an important
role of autophagy in the development of fibrosis and NASH, we
report herein that hepatocyte-specific ASK1-knockout mice
develop liver fibrosis as evidenced by high collagen deposition,
elevated protein levels of a-SMA, and increased expression of
Col1a1. Fibrosis formation was paralleled by elevated expression
of inflammatory cytokines such as Il-6 and Tgfb1. Thus, ASK1
suppresses the formation of NASH and fibrosis formation, poten-
tially via activation of autophagy.
Elevated liver lipid accumulation in ASK1Dhep mice was observed
after 20 weeks of HFD feeding. Of note, liver steatosis was not
enhanced in ASK1Dhep mice after a shorter period of HFD, i.e.,
6 weeks (Appendix Fig S5A). In these mice, liver inflammation (i.e.,
lower Tnf-a expression) was reduced and glucose tolerance
improved when compared to control littermates (Appendix Fig S5B
and C). Consequently, ASK1 depletion may have a beneficial effect
in an earlier phase of high-fat feeding, whereas it negatively affects
liver lipid metabolism and promotes NASH after prolonged high-fat
diet intake.
In contrast to our findings, a recent study reported a positive
effect of hepatic ASK1 (and JNK1) ablation in the development of
steatohepatitis in HFD-fed mice (Wang et al, 2017b; Zhang et al,
2018). Such discrepancy may be partially explained by differences
in the experimental setup as we used a HFD mainly consisting of
coconut oil, while Wang et al (2017b) used a HFD containing lard.
In addition, sucrose content was 50% higher in the diet used in the
present study. Based on the phenotypic transformation observed in
our mouse model depending on HFD exposure time, it would be
interesting to investigate whether a longer period of HFD feeding
induces deleterious effects in aforementioned mouse models (Zhang
et al, 2016a; Wang et al, 2017b). Recent clinical trials have identi-
fied decreased autophagy markers such as elevated numbers of LC3-
II puncta and increased protein levels of p62 in liver of patients with
steatosis or NASH (Gonzalez-Rodriguez et al, 2014). Such data
suggest that autophagy may also be critically involved in the devel-
opment of hepatic steatosis and NASH in humans. Indeed, mole-
cules targeting autophagy revealed beneficial effects on NASH both
in animal and clinical studies (Allaire et al, 2019). However, tested
drugs may have affected other pathways than autophagy and there-
fore suffered from specificity toward the latter. Therefore, identifi-
cation of more selective and hepatocyte-specific activators of
autophagy to tackle NASH is warranted. In line with a role of autop-
hagy in NASH, we found significant negative correlations between
liver ASK1 expression and liver fat content as well as circulating
ALAT levels in human subjects. Moreover, decreased ASK1 expres-
sion was associated with increasing NASH scores, whereas ASK1
correlated positively with the autophagy markers ATG5, ATG7, and
ATG12. These data support a protective role for liver-expressed
ASK1 in the development of hepatic steatosis as well as NASH in
humans. In contrast, treatment with the ASK1 inhibitor selonsertib
(in combination with the humanized monoclonal antibody directed
against lysyl oxidase-like molecule 2 simtuzumab) was recently
reported to reduce liver fibrosis in a subgroup of patients with mani-
fest NASH and moderate-to-severe fibrosis (Loomba et al, 2018),
suggesting that ASK1 inhibition may be a useful strategy to halt or
partly reverse evolved liver pathologies at least in some patients.
Although both selonsertib and the ASK1 inhibitors used in this study
(MSC 2032964A) are potent and selective ASK1 inhibitors, their dif-
ferent molecular structure may explain observed differences. In
addition, ASK1 may not only be inhibited in the liver but also be
inhibited in other organs such as adipose tissue. Of note, we have
evidence that inhibition of ASK1 in white adipose tissue may
promote browning and, thus, may reduce hepatic lipid accumula-
tion and improve glucose metabolism. Clearly, further studies inves-
tigating the role of ASK1 in the development and/or reversal of
NASH and fibrosis are warranted.
Taken together, we identify a beneficial role for liver-specific
ASK1 expression in the prevention of obesity-associated hepatic
steatosis and liver fibrosis potentially through induction of autop-
hagy that may have translational therapeutic implications to tackle
the development of NAFLD and liver fibrosis in humans.
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Materials and Methods
Human studies
The expression of ASK1 and ATG5, ATG7 and ATG12 mRNAs was
measured in livers of lean subjects and patients who underwent
open abdominal surgery for Roux-en-Y bypass, sleeve gastrectomy,
or elective cholecystectomy. Liver biopsies were taken during
surgery, immediately snap-frozen in liquid nitrogen, and stored at
80°C until further preparation. Measurement of total body and
liver fat, tissue sample handling, and analysis of blood samples
including measurement of serum adiponectin and leptin concentra-
tions has been performed as described previously (Kloting et al,
2010; de Guia et al, 2015). Serum alanine aminotransferase
(ALAT) was photometrically measured using the Cobas C 6000
System (Roche, Germany). All investigations have been approved
by the ethics committee of the University of Leipzig (363-10-
13122010 and 017-12-230112) and were carried out in accordance
with the Declaration of Helsinki, and all study participants
provided witnessed written informed consent before entering the
study. Expression of human ASK1, ATG5, ATG7, and ATG12
mRNAs was measured by qRT–PCR using Assay-on-Demand gene
expression kits (ASK1 (Hs01039896_m1), ATG5 (Hs00169468_m1),
ATG7 (Hs00197348_m1), and ATG12 (Hs04980076_s1); Applied
Biosystems, Darmstadt, Germany), and fluorescence was detected
on an ABI PRISM 7000 Sequence Detector (Applied Biosystems).
Expression of ASK1, ATG5, ATG7, and ATG12 mRNAs was calcu-
lated relative to the expression of 18S rRNA (Hs99999901_s1;
Applied Biosystems).
Materials and reagents
Sodium palmitate (Palm), bovine serum albumin (BSA), rapamycin
(Rap), bafilomycin A1 (Baf), and carbon tetrachloride (CCl4) were
obtained from Sigma-Aldrich (Buchs, Switzerland). BODIPY 493/
503, ASK1 inhibitor (MSC 2032964A), was purchased from Bio-
Techne AG (Zug, Switzerland); Hoechst and Lipofectamine 2000
were purchased from Invitrogen (Reinach, Switzerland). RNA
extraction kits were obtained from Promega (Du¨bendorf, Switzer-
land). QPCR master mix was purchased from Promega. SYBR green
was obtained from Roche Diagnostics (Rotkreuz, Switzerland).
Animals
To obtain mice with a conditional knockout allele of ASK1, exon 14
was targeted. Embryonic stem (ES) cell clone with exon 14 flanked
by loxP site and a FRT-flanked selection cassette were obtained from
the European Conditional Mouse Mutagenesis Program (EUCOMM).
Morula aggregation for producing chimeric mice from ES cells
(B6 background, TyrC+) and foster mothers (Tgv, TyrC) was
performed at Institute of Laboratory Animal Science, University of
Zurich. Then, chimeric mice were crossed with B6-albino mice
(TyrC). Their offspring with successful germ-line transmission
(black mice) were screened for the presence of the inserted loxP
sites by PCR. Mice heterozygous for floxed ASK1 were subsequently
inbred to produce homozygous mutant mice. The FRT-flanked selec-
tion cassette was removed by crossbreeding the floxed ASK1 mice
with Flpo deleter mice (Kranz et al, 2010).
Hepatocyte-specific ASK1-knockout (ASK1flox/flox, Alb-Cre+/;
ASK1Dhep) mice were generated by crossing homozygous ASK1
floxed (ASK1flox/flox, ASK1F/F) mice with mice carrying the Cre
recombinase transgene under the control of the albumin promoter
(C57BL/6J-Tg (Alb-Cre) mice). Littermate mice (ASK1flox/flox, Alb-
Cre/; ASK1F/F) without albumin-Cre recombinase (Cre) expres-
sion were used as a control groups. Liver-specific ASK1-overexpres-
sing mice were generated in collaboration with the company
PolyGene (Ru¨mlang, Switzerland). The cDNA of ASK1 was inserted
into the ROSA26 locus together with a loxP-flanked stop cassette
(ROSA26-ASK1F/F). ASK1 overexpression in the liver was induced
via Cre-lox-mediated excision of the stop cassette by breeding
ROSA26-ASK1F/F mice to aforementioned Alb-Cre mice (ROSA26-
ASK1+hep).
All animal studies were conformed to the Swiss animal protec-
tion laws and were approved by the Cantonal Veterinary Office in
Zurich, Switzerland. Six- to 26 week-old-male mice were used for
experiments. Mice were housed in a pathogen-free animal facility
on a 12-h dark/light cycle and fed ad libitum with regular chow diet
(Provimi Kliba, Kaiseraugst, Switzerland) or a high-fat diet
(58 kcal% fat w/sucrose Surwit diet, D12331, Research Diets, New
Brunswick, NJ, USA). The latter was started at the age of 6 weeks
and maintained for either 6 or 20 weeks. In experiments, chow-fed
control mice were at the same age as HFD-fed mice. Mice receiving
the ASK1 inhibitor were allocated to groups based on body weight
(similar mean  SD in starting body weight between the groups).
Genotyping of animals
All mice were genotyped by PCR with primers amplifying the Cre
transgene (generating 310 bp Cre allele products and 510 bp
control) and ASK1 (generating 191 bp wild-type and 216 bp
“floxed” allele products).
ASK1 inhibitor administration
ASK1 inhibitor was administered as previously described (Guo et al,
2010). In brief, ASK1 inhibitor was dissolved in 0.5%
carboxymethylcellulose/0.25% Tween 20 in distilled water. Male
C57BL/6J littermate mice fed a HFD for 11 weeks were treated
either with ASK1 inhibitor (30 mg/kg body weight) or with control
(0.5% carboxymethylcellulose/0.25% Tween 20 dissolved in
distilled water) during the last 5 weeks of HFD feeding by oral
gavage once/day for 5 days per week. ASK1 inhibitor-treated mice
were fasted for 5 h before tissue sampling.
CCl4 administration
Carbon tetrachloride (CCl4; 0.5 ll/g body weight, dissolved in corn
oil at a ratio of 1:3) was intraperitoneally (i.p.) injected three times
per week for 6 weeks.
Liver triglyceride measurement
Mice were fasted overnight for tissue sampling. Hepatic triglyceride
(TG) was extracted from 50 to 100 mg liver by using chloroform
and methanol, 2:1 (v/v; Wueest et al, 2016), and TG concentration
was measured with an enzymatic assay kit (Roche Diagnostics).
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ASK1 inhibitor-treated mice were fasted for 5 h before tissue
sampling.
Glucose tolerance tests
Mice were fasted overnight, and baseline glucose levels were
measured. Thereafter, glucose (2 g/kg body weight) was injected
intraperitoneally (i.p.) and blood glucose concentration was
measured from tail-tip blood after 15, 30, 45, 60, 90, and 120 min
by using a glucometer (Accu-Chek Aviva; Roche Diagnostics).
Metabolic plasma analysis
Individual mouse body weights were monitored every week. Mice
were fasted overnight for blood sampling. ASK1 inhibitor-treated
mice were fasted for 5 h before blood sampling. Free fatty acid
(FFA), glycerol, triglyceride (TG), total cholesterol (TC) alanine
transaminase (ALT), and aspartate aminotransferase (AST) levels
were measured by Roche Cobas Mira (Sawgrass Drive, Bellport,
NY, USA). The commercial kits were obtained from Diatools AG
(Villmergen, Switzerland). Insulin was determined as previously
described (Konrad et al, 2007). Plasma cytokine tumor necrosis
factor alpha (TNF-a), interleukin 10 (IL-10), interleukin 6 (IL-6),
and keratinocyte chemoattractant (KC/CXCL1) were measured
using MSD technology (Meso Scale Discovery, Gaithersburg, MD,
USA). All analyses were carried out according to manufacturer’s
protocols.
Histological analysis
Liver tissue was fixed in 4% formaldehyde solutions and embedded
in paraffin. Liver sections (4 lm thick) were stained with hema-
toxylin and eosin (H&E) or Sirius red (Sakaida et al, 2004). Sirius
red-positive areas were measured and quantified using ImageJ soft-
ware (Inokuchi-Shimizu et al, 2014).
Immunofluorescence
Liver sections (4 lm thick) were blocked and incubated overnight
with primary LC3A/B (#12741, Cell Signaling Technology, Leiden,
the Netherlands) or anti-actin a-smooth muscle (A5228, Sigma-
Aldrich) antibody and a corresponding secondary Cy3 antibody.
Immunofluorescence images were obtained by using a fluorescence
microscope (Axioplan 2 imagining) with AxioVision software
(version 4.6).
Cell culture
Human hepatocellular carcinoma HepG2 cells were plated on black
96-well plates with clear bottoms at 1.2 × 104 cells/well in DMEM
containing 1 g/l D-glucose, L-glutamine, pyruvate, 10% fetal bovine
serum (FBS), and 1% antibiotics. After 48 h, 60–80% confluent cells
were treated with or without 0.4 mM BSA, 0.4 mM palmitate, and
1 mM rapamycin for 24 h in serum- and antibiotic-free media. The
cells were fixed in 4% formaldehyde solution and stained for lipid
droplet accumulation (BODIPY 493/503) and nuclei (Hoechst). Fluo-
rescence images were taken with the Operetta high-throughput
imaging system, and lipid droplet accumulation was quantified
using automated image-based analysis with Harmony software
(Meissburger et al, 2011; Challa et al, 2012, 2015).
Cell transfection
For the RNA interference assay, 15 ll Opti-Mem and 200 nM small
interfering RNA targeting ASK1, siRNA (siASK1), or control siRNA
(siCtrl) were mixed and 60–70% confluent cultured HepG2 cells
were transfected using Lipofectamine 2000 with antibiotic-free
media. After 24 h, the medium was changed and the cells were
treated with or without 0.4 mM BSA, 0.4 mM palmitate, and 1 mM
rapamycin in serum-free medium. Then after 24 h of treatment, the
cells were fixed with 4% formaldehyde, blocked, and incubated O/n
with primary LC3A/B antibody (#12741, Cell Signaling Technology)
and Cy3 anti-rabbit secondary antibody was used for LC3-II punctu-
ate staining. Lipid droplets were stained as mentioned above.
Fluorescent images were taken, and automated lipid droplet quan-
tification was performed with the Operetta high-throughput imaging
system (Meissburger et al, 2011; Challa et al, 2012, 2015). SMART-
pool ASK1 siRNA was purchased from Thermo Scientific (Reinach,
Switzerland) and Microsynth (Balgach, Switzerland; sequences are
available upon request).
Experiments in primary mouse hepatocytes
Male 10-week-old mice were anesthetized, and the inferior vena cava
was cannulated with a 23G needle. The liver was perfused with 25–
30 ml of pre-warmed perfusion buffer (1× HBSS, 25 mM HEPES,
0.5 mM EGTA, pH 7.4). Thereafter, the liver was digested by
10–15 ml of pre-warmed digestion buffer [DMEM containing 1 g/l D-
glucose and 265 mg/l of CaCl2 (Thermo Fisher Scientific, Waltham,
MA, USA, cat # 31885), 15 mM HEPES, 1% antibiotics, and 50 CDU/
ml of collagenase IV (Sigma cat. # C5138)]. The liver was removed and
the hepatocytes released into 10 ml of ice-cold isolation/plating media
(DMEM containing 1 g/l D-glucose, 10% FBS, 1% antibiotics) by shak-
ing. Cells were suspended, filtered through a 100-lm cell strainer, and
centrifuged at 50 × g at RT for 2 min. The pellet was washed twice
with 20 ml of ice-cold isolation/plating media, suspended in 5 ml of
ice-cold 1× HBSS, and added to 5 ml of a Percoll gradient solution
[4.5 ml of Percoll (Sigma cat. # P1644) and 0.5 ml of 10× HBSS].
Following centrifugation for 10 min at 50 × g at RT, the pellet was
washed in 10 ml of ice-cold isolation/plating media. The pellet was
suspended in 10 ml of pre-warmed isolation/plating media, and
primary hepatocytes were plated on black 96-well plates with clear
bottoms at 3.5 × 104 cells/well. After 6 h, media was changed to
serum-free media and cells were treated with or without 0.4 mM BSA,
0.4 mM palmitate, 10 nM bafilomycin A1, or 1 mM rapamycin. After
24 h, cells were fixed with 4% formaldehyde, blocked, and incubated
o/n with primary LC3A/B antibody (#12741, Cell Signaling Technol-
ogy). Subsequently, cells were incubated with a Cy3 anti-rabbit
secondary antibody. Fluorescence images were taken, and lipid
droplets were quantified as mentioned above.
RNA extraction and quantitative real-time PCR
Total RNAwas extracted using RNA extraction kit from Promega accord-
ing to the manufacturer’s protocol. 1.0 lg of total RNA was converted
into first-strand cDNA using GoScript Reverse Transcription kit (Takara
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or Promega, Switzerland). The following primers were used: Acox1,
Mm00443579_m1; Cpt1a, Mm00550438_m1; Ppara, Mm00627559_m1;
Mcp-1, Mm00441242_m1; Tnf-a, Mm00443258_m1; Il-6, Mm00446190_m1;
F4/8, Mm00802529_m1; Plin, Mm00558672_m1; Fas, Mm00662319_m1;
Acc1, Mm01304257_m1; Srebp1, Mm00550338_m1; Hsl, MM00495
359_m1; Il-1b, Mm00434228_m1; Col1a1, Mm00801666_g1; Tgfb1,
MM01178820_m1 (Applied Biosystems, Foster City, CA, USA). For
Vldlr, real-time PCR quantification was performed using fast SYBR
Green master mix and gene-specific primer sets (sequences are avail-
able upon request). Expression of the respective genes was normal-
ized to 18S rRNA (Applied Biosystems) as an internal control.
Western blot analysis
Tissue samples and cultured cells were lysed in RIPA buffer and
centrifuged at 24,000 g for 10 min, and protein concentrations were
measured. Equal amounts of proteins were resolved by SDS–PAGE
(8–15%) gel and transferred onto a nitrocellulose membrane as
previously described (Wueest et al, 2010; Challa et al, 2012; Item
et al, 2017). The following primary antibodies were used: anti-ASK1
(ab45178, Abcam, Cambridge, United Kingdom; diluted 1:1,000),
anti-phospho-ASK1 (Thr 845, sc-109911; diluted 1:2,000),
anti-phospho-JNK (G-7; sc-6254; diluted 1:2,000), and anti-COL1A1
(sc-293182; diluted 1:200) were obtained from Santa Cruz Biotech-
nology, Heidelberg, Germany. Anti-BCN1 (NB110-87318SS; Novus,
Abingdon, United Kingdom; diluted 1:1,000), anti-phospho-p38
MAPK (Thr180/Tyr182, 9211; diluted 1:1,000), anti-p38 MAPK
(9212; diluted 1:1,000), anti-JNK2 (56G8; 9258; diluted 1:1,000),
anti-ATG12 (D88H11; 4180; diluted 1:1,000), anti-phospho-BCN 1
(Ser15; 3825; diluted 1:1,000), anti-LC3A/B (D3U4C; 12741; diluted
1:1,000), anti-SQSTM1/p62 (5114; diluted 1:1,000), and anti-HSP90
(4877; diluted 1:1,000) were obtained from Cell Signaling Technol-
ogy. Anti-Actin (MAB1501, Merck Millipore, Darmstadt, Germany;
diluted 1:5000), anti-GAPDH (10494-1-AP, Proteintech, Rosemont,
IL, USA; diluted 1:1000). Thereafter, membranes were incubated
with corresponding secondary HRP–conjugated antibodies. Actin,
HSP90 and GAPDH were used as a loading control. The proteins
were developed and quantified with Aida Image analyzer version
(version 3.52).
Data analysis
All data are expressed as mean  SEM. The significance was
determined using a two-tailed, unpaired Student’s t-test, Spearman
correlation, one-way ANOVA with Newman–Keuls correction for
multiple group comparisons, or two-way ANOVA with Bonferroni
multiple comparisons. Statistical tests were calculated using
the GraphPad Prism 5.0 (GraphPad Software, San Diego, CA, USA). P-
values < 0.05 were considered significant. Exact P-values are listed in
Appendix Table S4. Power calculation analysis was not performed.
Sample size was determined based on previous experiments performed
in our laboratory. The evaluator was blinded to the identity of a
specific sample as far as the nature of the experiment allowed it.
Data availability
The datasets supporting the findings of this study are available from
the authors on request.
Expanded View for this article is available online.
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